{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-06-10&hansardHeading=Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-06-10&hansardHeading=Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-06-10&_metadata=all&hansardHeading=Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-06-10&_page=0&hansardHeading=Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-06-10&hansardHeading=Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-06-10&hansardHeading=Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access", "items" : [{"_about" : "http://data.parliament.uk/resources/1522764", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1522764/answer", "answerText" : {"_value" : "<p>The Voluntary Scheme for Branded Medicines Pricing and Access includes a 36 month exemption from payments for drugs containing a new active substance, starting once the marketing authorisation has been granted. Treatment of new active substances under a future voluntary scheme is subject to negotiation.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
        }
        , "answeringMemberConstituency" : {"_value" : "Newark"}
        , "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
        , "dateOfAnswer" : {"_value" : "2022-10-25", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-10-25T16:47:32.28Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-10-17", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Voluntary Scheme for Branded Medicines Pricing and Access"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Voluntary scheme for branded medicines pricing and access, whether her Department has made an assessment of the potential merits of an exemption from payments for new active substances from that scheme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3985", "label" : {"_value" : "Biography information for Robert Halfon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harlow"}
      , "tablingMemberPrinted" : [{"_value" : "Robert Halfon"}
      ], "uin" : "64035"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}